These mutations consisted of 19 KRAS (24.7%), 10 EGFR (13%), five BRAF (6.5%), four PIK3CA (5.2%), one HER2 (1.3%), one HER4 (2.2%) and none for HER3. mEGFR, mBRAF and mHER2 were present exclusively in adenocarcinomas while mKRAS were more frequent in adenocarcinoma and large cell histologies. The gene discussed is PIK3CA; the disease is adenocarcinoma.